This approval enhances Alembic Pharma’s portfolio, which now totals 216 ANDAs from the USFDA, including 188 final and 28 ...

Alembic Pharma share price surged after the United States Food and Drug Administration (USFDA) gave final approval for ...

This is the first step in the direction of the budget announcement this year to provide internships to one crore youth in the ...

Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) Alcaftadine Ophthalmic Solution.

The approved ANDA is therapeutically equivalent to GlaxoSmithKline LLC's Lamictal XR extended-release tablets in strength of ...

The stock hits an intraday high on Thursday, October 3, 2024, after getting approval from USFDA for general medication drug.

Mahindra Group, Max Life Insurance, and Alembic Pharmaceuticals are leading internships under a new central scheme, with ...

Lamotrigine extended-release tablets have an estimated market size of $163 million, as per data for twelve months ending June ...

The estimated market value for Lamotrigine Extended-Release Tablets is approximately $163 million for the year ending June ...

This approval adds to Alembic Pharma's growing portfolio, which now includes 216 ANDA approvals from the USFDA, comprising ...

Vadodara: Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug ...

Alembic has a cumulative total of 216 ANDA approvals (188 final approvals and 28 tentative approvals) from USFDA.